SmithKline Beecham LYMErix Posts $18 Mil. In First Quarter Sales
Executive Summary
SmithKline Beecham's Lyme disease vaccine is off to a "solid" start in the U.S., the company said.
You may also be interested in...
GSK Lymerix Withdrawn: Production Stopped, Inventory To Be Discarded
GlaxoSmithKline has ceased production of Lymerix and will not be selling its remaining inventory of the Lyme disease vaccine
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011